Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06401356 Not yet recruiting - Solid Tumor Clinical Trials

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide continued access to treatment with pelabresib for patients who previously received pelabresib in a parent study and to continue collecting safety and efficacy information. By collecting efficacy information, the study team monitors if pelabresib helps the patient with their disease. Additionally, survival follow-up data will be collected. Survival follow-up collects information on the patient's leukemia-free survival and overall survival status (life span) during and after the treatment is ended. If a patient stopped pelabresib treatment on the parent study for any other reason than participation in this study, they will not receive further pelabresib treatment, but they can enter the study for survival-follow up only.

NCT ID: NCT06206915 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Study of XZ120 in Malignant Tumors

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.

NCT ID: NCT06038058 Not yet recruiting - Clinical trials for Advanced Malignancies

A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BRY812 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BRY812 for injection in patients with advanced malignancies. Patients will receive treatment every 3 weeks until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.

NCT ID: NCT05987605 Not yet recruiting - Clinical trials for Advanced Malignancies

Clinical Study of 1A46 Drug Substance

Start date: October 1, 2023
Phase: Phase 1
Study type: Interventional

A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell non-Hodgkin's lymphoma (B - NHL)

NCT ID: NCT05351697 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Clinical Study of BR105 Injection

BR105-I
Start date: April 2022
Phase: Phase 1
Study type: Interventional

A phase 1, dose escalation and dose expansion study of BR105 in patients with advanced malignancies.